JNJ Options Signal Bullish Momentum: Target $210 Calls as 30-Month Trial Data Fuels Optimism

• JNJ surges 2.33% to $204.62, trading near its 210.51 Bollinger Band upper bound
• Call open interest dominates next Friday’s chain, with 4,614 contracts at $210
• 30-month CARTITUDE-4 trial data and Tecvayli combo therapy drive near-term catalysts

The stock’s 2.3% intraday pop isn’t just noise—it’s a signal. Options traders are pricing in a sharp move above $210, while technicals hint at a potential breakout. Let’s break down why this could be a pivotal day for JNJ.Bullish Calls Stack Up Against Deep Puts: What Traders Are Bidding

Next Friday’s options chain tells a clear story: 4,614 contracts at the $210 call (JNJ20251219C210) dwarf the 3,225 puts at $190. This isn’t just a call/put ratio tilt—it’s a concentrated bet on a $15+ rally. The 30-day moving average (197.01) and 200D MA (170.65) are both far below current price, reinforcing the long-term bullish trend. But don’t ignore the 2,400 puts at $185: someone’s hedging a worst-case scenario, likely tied to legal or MedTech risks. The key takeaway? Retail and institutional players are pricing in a strong upside move, but volatility remains a wildcard.

Trial Triumphs Validate the Bull Case

The CARTITUDE-4 and MajesTEC-3 data isn’t just academic—it’s a revenue catalyst. 80% progression-free survival at 30 months for CARVYKTI? That’s the kind of number that turns skeptics into believers. Combine that with Tecvayli’s mortality risk reduction and RYBREVANT’s lung cancer win in Asia, and JNJ’s Innovative Medicine segment looks like a cash engine. The stock’s 41.2% YTD gain isn’t a fluke; it’s a response to real-world results. But here’s the catch: patent cliffs for Stelara and Ibrance (PFE’s problem, not JNJ’s) still loom in 2026. For now, though, the news flow and options activity are in sync.

Trade Ideas: Calls for the Bold, Stock for the Patient

For options traders: JNJ20251219C210 is the play. With the stock at $204.62 and Bollinger Bands squeezing tight, a break above $205 could trigger a rush to these calls. Target a 5-7% move by Friday’s close. If you prefer the stock, enter near $201.89 (middle Bollinger Band) with a stop just below today’s low ($200.18). A close above $207.50 would validate the breakout, aiming for $210 as the next level. For the risk-averse: JNJ20251219P190 offers downside protection if legal worries resurface.

Volatility on the Horizon: Ride the Wave or Ride It Out

JNJ isn’t just a "blue-chip safe play" anymore—it’s a momentum story. The options market is pricing in a 5% move by Dec 19, and the fundamentals back it. But don’t ignore the puts at $190: they’re a reminder that MedTech headwinds and talc lawsuits still hang over the stock. For now, though, the 30-month trial data and a bullish technical setup make this a high-conviction trade. As the saying goes, "the trend is your friend"—and right now, JNJ’s friends are all bullish.